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Abstract-Human neutrophils have been reported to possess both aZ- and &-adrenoceptors. While 
activation of &adrenoceptors is known to inhibit jv-formyl-L-methionyl~L~leucyl-L-phenylalanine 
(fMLP)-induced superoxide anion (0;) production, the functional role of a;-adrenoceotors is not 
known: We studied-the effects of a r&$ of structu&ly unrelated cuz-adrenocepior agonisis on fMLP- 
induced 0; production and UTP-induced increases in cytosolic free calcium concentration ([Caz+li) in 
human neutrophils. No effect of qadrenoceptor agonists was seen on either fMLP-induced 0; 
production or UTP-induced increases in [Ca*+]i. qAdrenoceptor agonists by themselves had no effect 
on either 0; production or [Ca’+]i. We then studied a model for neutrophils, differentiated HL-60 cells 
and human erythroleukaemia (HEL) cells, a cell line known to uossess a;-adrenoceutors. While the 
cu,-adrenoceptor agonists 5-br~mo-6~(2-imidazolin-2-ylamino)-qu~noxaline <UK 143&) and 5-allyl-2- 
amino- 5,6,7,8- tetrahvdro-4H-thiazo10-14.5-dlazeoin-dihvdrochloride increased the ICaZ+l; in HEL cells. I,~~~~~.~~ ~_, 
they had no effect by themselves on e&e; [da’+]: or UT&nduced increases in [Cai+li n differentiated 
HL-60 cells. Activation of high-affinity GTPase by UK 14304 was seen in membranes from HEL cells 
but not in membranes from differentiated HL-60 cells. Similarly, a selective a2-adrenoceptor antagonist, 
[‘H]2-(2-methoxy-l,4-benzodioxan-2yl)-2 imidazoline, bound specifically and saturably to membranes 
from HEL cells, but not to membranes from HL-60 promyelocytes or differentiated HL-60 cells. Taken 
together, these data suggest hat neither HL-60 promyelocytes nor differentiated HL-60 cells possess 
cu,-adrenoceptors, and that the lack of functional responses to a2-adrenoceptor agonists in human 
neutrophils is due to the absence of cY,-adrenoceptors. 
Human neutrophils and HL-60 leukaemic cells 
possess receptors for the chemotactic peptide 
N - formyl - L - methionyl - L - leucyl - L - phenylalanine 
(fMLPt) which activates a superoxide (OF)-forming 
NADPH oxidase (EC 1.6.99.9) via G-proteins (for 
reviews see Refs l-3). fMLP-stimulated 0; 
production is inhibited by activation of receptors 
linked to stimulation of adenylyl cyclase (EC 4.6.1.1; 
e.g. /32-adrenoceptors, ee Ref. 1). In contrast, the 
role of receptors linked to inhibition of adenylyl 
cyclase in modulating superoxide production is not 
known. Human neutrophils have been reported to 
have binding sites for a2-adrenoceptors [4] and 
modulation of adenylyl cyclase activity by m2- 
adrenergic drugs has also been reported in these 
cells [4,5]. However, the effect of a*-adrenergic 
agonists on fMLP-stimulated 0, production has not 
been reported. Therefore, we studied the effects of 
a2-adrenoceptor agonists on fMLP-stimulated 0, 
production and its modulation by the cu-adrenoceptor 
agonist isoprenaline. In addition, we studied a 
model of neutrophils, HL-60 promyelocytes and 
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t Abbreviations: BHT920,5-allyl-2-amino-5,6,7,8- tetra- 
hydro-4H-thiazolo-[4,5-djazepin-dihydrochloride; [Ca2+li, 
cytosolic free Ca2+ concentration; db-CAMP, dibu- 
tyryl cyclic AMP; DMSO, dimethyl sulphoxide; fMLP, N- 
formyl-L-methionyl-L-leucyl+phenylalanine; Fura-2/AM, 
Fura- acetoxymethylester; HEL cells, human erythro- 
leukaemia cells; O;, superoxide anion; RX821002, 2-(2- 
methoxy-1,4-benzodioxan-2yl)-2 imidazoline; UK 14304, 
5-bromo-6-(2-imidazolin-2-ylamino)-quinoxaline. 
differentiated HL-60 cells (see Ref. l), and a cell 
line known to have both a2-adrenoceptors and 
functional responses to m2-adrenoceptor activation, 
human erythroleukaemia (HEL) cells [6]. Fur- 
thermore, we studied the effects of crz-adrenoceptor 
agonists on high affinity GTPase (EC 3.6.1.-) and 
binding of [3H]RX821002, aspecific ai-adrenoceptor 
ligand, to membranes from HEL cells and HL-60 
cells. We show here that, unlike in HEL cells, there 
is no evidence for the presence of o!2-adrenoceptors 
in human neutrophils and HL-60 cells. 
MATERIALS AND METHODS 
Materials. fMLP, UTP, ATP, adrenaline-HCl, 
isoprenaline-HCl, clonidine-HCl, oxymetazoline- 
HCl, phentolamine-HCl, yohimbine-HCl and 
thrombin were all obtained from Sigma Chemie 
(Deisenhofen, Germany). Fura- acetoxyme- 
thylester (Fura-2/AM) was purchased from Boehrin- 
ger Mannheim (Mannheim, Germany). 5-Allyl-2- 
amino - 5,6,7,8 - tetrahydro - 4H - thiazolo - [4,5 - d]- 
azepin-dihydrochloride (BHT 920) was a kind gift 
of Boehringer Ingelheim (Ingelheim, Germany). 
5 - Bromo - 6 - (2-imidazolin - 2-ylamino) - quinoxaline 
(UK 143041 was a kind gift of Pfizer (Sandwich, 
U.K.). [ H]2-(2-Methoxy-l,4-benzodioxan-2y1)-2 
imidazoline ([3H]RX821002, 57 Ci/mmol) was 
obtained from Amersham (Braunschweig, 
Germany). All other reagents were of analytical 
grade or the best available commercial grade and 
obtained from standard commercial suppliers. Unless 
otherwise stated, substances were initially dissolved 
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in deionized water and stock solutions were of 
10 mM. Adrenaline was dissolved in 1 mM HCI, 
fMLP was dissolved in dimethyl sulphoxide (DMSO) 
and Fura-2fAM was dissolved in DMSO to give a 
2 mM stock. Stock solutions were stored at -20”. 
Preparation of human neutrophils. Heparinized 
blood was obtained by venipuncture from healthy 
volunteers of either sex who had taken no drugs for 
at least 3 weeks. Neutrophils were isolated by 
dextran sedimentation and centrifugation through 
Ficoll-hypaque [7]. Cell preparations contained more 
than 98% viable neutrophils as judged by Trypan 
blue dye exclusion and Pappenheim-stained smears. 
Cell culture. HL-60 cells were grown in suspension 
culture in RPMI-1640 medium su 
P 
plemented with 
10% (v/v) horse serum, 1% (v v) non-essential 
amino acids, 2 mM L-glutamine, 50 U of penicillin/ 
mL and 50 ,ug of streptomycin/ml in a humidified 
atmosphere with 7% COr at 37”. To induce 
differentiation, HL-60 cells were seeded at a density 
of 1 x 106/mL and were cultured for 48 hr in the 
presence of 0.2 mM dibutyryl CAMP (db-CAMP) or 
for 120 hr in the presence of 160 mM DMSO [8,9]. 
HEL cells were grown identically, except that 10% 
(v/v) foetal calf serum was used instead of horse 
serum [lo]. Cells were harvested by centrifugation 
for 10 min at 25Og. Cell preparations contained 
more than 90% viable cells as judged by Trypan 
blue exclusion. 
0, production. 0; production was monitored by 
continuous measurement of ferrycytochrome c 
reduction that was inhibitable by superoxide 
dismutase (EC 1.15.1.1), using an Uvikon 810 
dual-beam spectrophotometer (Kontron, Eching, 
Germany). Reaction mixtures (0.5 mL) contained 
1 x lo6 neutrophils, 100 PM ferricytochrome c and 
a buffer consisting of 138 mM NaCl, 6mM KCl, 
1 mM MgCl*, 1 mM CaClr, 1 mM Na2HP04, 5 mM 
NaHCOs, 5.5 mM glucose and 20mM HEPES 
(adjusted to pH 7.4 with NaOH). Reaction mixtures 
were preincubated at 37” for 3 min. 0; production 
was initiated by addition of fMLP. Test substances 
or their solvents were added 3 min before fMLP 
except for isoprenaline, which was added 15 set 
before addition of fMLP, and in some experiments 
ai-adrenoceptor agonists were substituted for fMLP. 
Maximal 0; production was calculated from the 
steady-state portions of the absorbance curves [7]. 
Measurement of [Ca*+]i. Cytosolic calcium con- 
centration [Ca2+]i was determined with the dye Fura- 
2/AM as described previously [lo, 111. Briefly, 
neutro 
1 x 10 P 
hils, HL-60 or HEL cells were suspended at 
cells/ml in a buffer consisting of 138 mM 
NaCl, 6mM KCl, 1 mM MgS04, 1 mM Na2HP04, 
5 mMNaHC03,5.5 mMglucoseand20 mMHEPES, 
pH 7.4, supplemented with 1% (w/v) bovine serum 
albumin. Fura-2fAM was added to give a final 
concentration of 4 PM and cells were incubated for 
10min at 37”. Thereafter, the cells were diluted to 
5 x lo6 cells/ml in the above buffer and incubated 
for a further 45 min. Following this incubation period 
the cells were diluted to 0.5 x lo6 cells/ml and were 
centrifuged for 10 min at 250 g to remove extracellular 
dye. The cells were then resuspended in the above 
buffer at 1 x 106cells/mL and kept at room 
temperature until measurement of [Ca’+]i. One 
millilitre of this suspension was added to acryl 
fluorescence cuvettes (Sarstedt, Niimbrecht, Germ- 
any), further diluted with 1 mL of the above buffer 
and CaC12 added to give a final concentration of 
1 mM. Fluorescence was determined at 37” under 
constant stirring at 103rpm, using a Ratio II 
spectrofluorometer(Aminco,SilverSpring,U.S.A.). 
Cells were incubated for 3 min at 37” prior to addition 
of stimuli. The excitation wavelength was 340 nm and 
the emission wavelength was 500 nm. Fluorescence 
signals were calibrated after lysis of the cells with 
0.1% (w/v) Triton X-100 (maximal fluorescence) 
and subsequent addition of 20 mM EGTA (minimal 
fluorescence). Peak cytosolic Cazt was calculated 
according to equation 6 in Grynkiewcz et al. [12]. 
Preparation of membranes. HL-60 or HEL cells 
were homogenized by nitrogen cavitation and 
membranes were prepared as described in Ref. 13. 
Aliquots of cell membranes were thawed and 
centrifuged for 10 min at 30,000 g and 4“ in 1.5 mL 
of 10 mM triethanolamine-HCl, pH 7.4. Membranes 
were suspended at either 0.2-0.4 (GTPase assay) or 
1.5-2.0 (binding assay) mg/mL in the above buffer 
and immediately used for the respective xperiments. 
Protein was determined by the method of Lowry et 
al. [14]. 
Measurement of high-afinity GTPase activity. [y- 
32P]GTP was synthesized according to the method 
of Johnson and Walseth [15]. High-affinity GTPase 
activity was measured according to the method of 
Seifert et al. [ll] with minor modifications. The 
reaction mixtures (100 pL) contained membranes 
(5.0-7.0 pg protein/tube), 0.5 PM [Y-~~P]GTP 
(0.1 &i/tube), 0.5 (HL-60 membranes) or 5 (HEL 
membranes) mM MgC12, 0.1 mM EGTA, 0.1 mM 
ATP, 1 mM adenosine 5’-[&y-imido]-triphosphate, 
5 mM creatine phosphate, 40 pg of creatine kinase, 
1 mM dithiothreitol and 0.2% (w/v) bovine serum 
albumin in 50 mM triethanolamine-HCl, pH 7.4. 
Preliminary experiments showed that the above 
MgC12 concentrations were optimal for studying 
stimulation of GTPase activity in HL-60 and HEL 
membranes. In addition, the reaction mixtures 
contained the various drugs and hormones at the 
final concentrations indicatedin Results. The reaction 
mixtures without [Y-~*P]GTP were preincubated at 
25” for 3 min, and the reaction was then started by 
addition of [Y-~*P]GTP. The reaction was terminated 
after 15 min by the addition of activated charcoal in 
20 mM KH2POb, pH 2.0. Low-affinity GTPase 
activity was determined in the presence of a high 
concentration of GTP (5OpM) and was subtracted 
from the total GTPase activity measured at 0.5 PM 
GTP. Low-affinity GTPase activity in HL-60 
promyelocytes,db-CAMP-andDMSO-differentiated 
HL-60 cells was less than 5% of total GTPase activity 
and less than 20% of the total GTPase activity in 
HEL cells (data not shown). 
Binding. Membranes were thawed and prepared 
as described above. The methoxy derivative of 
idazoxan, [3H]RX821002, was used as the probe as 
it appears to bind to all described subtypes of CY~- 
adrenoceptors with high affinity and shows low non- 
specific binding [16-191, and appears to provide 
better resolution of low receptor numbers than 
[3H]yohimbine [17, 181. Tota1[3H]RX821002binding 
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Fig. 1. ‘Effects of BHT 920 and isoprenaline on fMLP- 
stimulated 0; production in human neutrophils. 0; 
production was initiated by the addition of fMLP at the 
concentrations indicated. BHT 920 was added 3 min before 
fMLP; isoprenaline was added 15 set before fMLP. (0) 
fMLP alone: (Cl) fMLP in the nresence of isourenaline 
(0.01 PM); (ijf6fLP in the presence of BHT 920’(10 PM); 
(m) fMLP in the presence of both BHT 920 and 
isoprenaline. The graph shows the results of a single 
experiment. The standard deviation for duplicates was 
generally less than 10% of the mean and has been omitted 
for clarity. Similar results were seen in at least four further 
experiments from different donors. 
was determined by incubation of membranes (50- 
70 pg/tube) in a buffer containing 0.5 mM MgC12, 
1 mM EDTA and 50 mM Tris-HCl, pH 7.4 (final 
volume 1OOpL). Non-specific binding was deter- 
mined in the presence of phentolamine (10yM). 
The assay solution was preincubated at 25” for 3 min 
without [3H]RX821002, and binding was initiated by 
addition of [3H]RX821002 at the concentrations 
indicated in Fig. 3. After 30 min the assay mixtures 
were filtered through fiberglass filters (Whatman 
GF/B) presoaked with 1% (w/v) polyethylene imine 
(Fluka, Buchs, Switzerland). The filters were washed 
twice with 5 mL of ice-cold buffer consisting of 
0.5 mM MgC12, 50 mM Tris-HCl, pH7.4. The 
radioactivity trapped on the filters was determined 
by liquid scintillation spectrophotometry. The 
number of sites (B,,,) and KD were determined 
from the Scatchard plot and non-linear curve fitting 
of the saturation curve using the program Sigmaplot 
4.0 (Jandel, U.S.A.). 
RESULTS 
Superoxide production 
DISCUSSION 
fMLP induced substantial and concentration- The aim of this study was to determine the 
dependent production of 0, in human neutrophils functional role of cu2-adrenoceptors in human 
(Fig. 1). The Padrenoceptor agonist isoprenaline myeloid cells. Neutrophils have been reported 
did not stimulate 0, production by itself, but to have a2-adrenergic binding sites [4]. 02- 
significantly inhibited 0, production stimulated by Adrenoceptor blockers have also been described as 
1 PM fMLP in a concentration-dependent manner enhancing accumulation of cyclic AMP in response 
with an lcso of approximately 3 nM and a maximum to noradrenaline [4]. Furthermore, a*-adrenoceptor 
of 30nM (data not shown). The cyZ-adrenoceptor stimulation has been reported to inhibit adenylyl 
agonist BHT 920 (10 PM) by itself did not stimulate 
0, production (data not shown) and did not alter 
either fMLP-stimulated 0, production or the 
isoprenaline-induced inhibition of fMLP-stimulated 
0, production (see Fig. 1). Similarly, BHT 920 
(0.1-10 PM) did not reverse the inhibition of fMLP- 
stimulated 0, production induced by isoprenaline 
(3 and lOnM, data not shown). Essentially similar 
results were obtained with the a*-adrenoceptor 
agonists UK 14304, oxymetazoline and clonidine (all 
at lOpM, data not shown). 
[Ca*+]i 
UTP (10 PM) induced consistent increases in 
[Ca2+]i n HEL cells, human neutrophils. HL-60 
promyelocytes and DMSO-differentiated HL-60 cells 
(Fig. 2). UK 14304 (10 PM) produced a substantial 
rise in [Ca2+]i in HEL cells (see Fig. 2). The effect 
of UK 14304 was inhibited by the selective ff2- 
adrenoceptor antagonist yohimbine (10 PM, see Fig. 
2). In contrast, in human neutrophils, HL-60 
promyelocytes and DMSO-differentiated HL-60 
cells, UK 14304 (10pM) was ineffective (see Fig. 
2). Similar results were seen with BHT 920 (10 PM) 
and adrenaline (1 PM) in the presence of propranolol 
(10pM) (data not shown). BHT 920 (10pM) and 
UK 14304 (10 PM) did not affect the UTP-induced 
increases in [Ca’+]i in neutrophils and DMSO- 
differentiated HL-60 cells (data not shown). 
GTPase activity 
Table 1 shows the effects of various substances on 
high-affinity GTPase, the enzymic activity of rx- 
subunits of G-proteins, in membranes from db- 
CAMP- and DMSO-differentiated HL-60 cells and 
HEL cells. High-affinity GTPase activity was 
significantly increased by fMLP in membranes from 
differentiated HL-60 cells and by thrombin in the 
membranes from HEL cells (Table 1). High-affinity 
GTPase activity in HEL membranes was also clearly 
activated by UK 14304 (see Table 1). This effect of 
UK 14304 was blocked by yohimbine (1 PM; data 
not shown). In contrast, UK 14304 had no effect on 
high-affinity GTPase activity in membranes from 
differentiated HL-60 cells (see Table 1). 
Binding 
Membranes from HEL cells showed saturable, 
specific high-affinity binding of [3H]RX821002, with 
a KD of 0.5 -+ 0.1 nM and a B,,, of 123 + 4 fmol/ 
mg protein (Fig. 3) which appear to correspond to 
the cuzA-adrenoceptor subtype [20]. Membranes from 
undifferentiated and differentiated HL-60 cells 
showed no saturable, specific high-affinity binding 
(see Fig. 3). 
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Fig. 2. The effect of the a*-adrenoceptor agonist UK 14304 on [Ca’+]i n HEL cells, neutrophils and 
HL-60 cells. In all panels the upper trace represents the effect of UTP (10 pM) on (Ca”+li in cells loaded 
with Fura-2/AM. In panel A the middle trace shows the effect of UK 14304 (10 PM) on [Ca*‘J in HEL 
cells. The lower trace shows the effect of UK 14304 in the presence of yohimbine (10~M). In panels 
B, C and D the lower trace shows the lack of effect of UK 14304 (10pM) on [Cazcli in human 
neutrophils, DMSO-differentiated HL-60 cells and HL-60 promyelocytes, respectively. Stimuli were 
added at the point indicated by an arrow. Experiments were performed in duplicate and similar results 
were seen in at least three further independent experiments. 
Table 1. The effect of the trz-adrenoceptor agonist UK 14304 on high affinity GTPase 
in membranes from HEL cells or HL-60 cells differentiated with DMSO or db- 
CAMP 
Control 
Thrombin 
NLP 
UK 14304 
High affinity GTPase activity (pmol Pi/mg proteinlmin) 
HL-60 cells differentiated with: 
HEL cells DMSO db-CAMP 
19-c3 22 2 4 15 26 
30 f 7* (61%) 
32 _’ $;49%) 23 r !?;46%) 
23 rc_ 3N’q23%) 23 + 5 (6%) 15 r 6 (0%) 
GTPase activity was determined by measurement of Y-~*P~ released from [y--‘*P]- 
GTP as described in Materials and Methods. Thrombin (1 U/mL), fMLP (1 PM) 
and UK 14304 (1OpM) were present where indicated. Stimuli were added 3 min 
before the reaction was initiated by addition of [y-3zP]GTP. 
ND indicates that the experiment was not performed. 
Values represent the means 2 SD of two to three experiments on separate 
membrane preparations. Determinations in each experiment were performed in 
quadruplicate. Values in brackets represent the percentage increase over basal 
GTPase activity. 
* Represents a significant difference from basal values (P > 0.05, Wilcoxon test). 
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Fig. 3. Specific binding of [3HH]BX821002 to membranes of 
HEL and HL-60 cells. Binding of f3HlRX821002 to 
membranes of HEL and HL-6Ocells waszperformed as 
described in Materials and Methods with f3HlBX821002 at 
the concentrations indicated. Non-spehfic a binding was 
determined with phentolamine (10 PM). Each point 
represents the average of two to three experiments on 
separate membrane preparations. Each experiment was 
performed in triplicate. Membranes from HEL cells (0) 
showed specific, saturable, high-affinity binding (Scatchard 
plot inset); non-specific binding at saturation was 19 2 5% 
of total. Membranes from HL-60 promyelocytes (0) or 
HL-60 cells differentiated with db-CAMP (B) or DMSO 
(+) showed no saturable high affinity binding. SD bars 
are omitted from the HL-60 curves for ctarity. 
cyclase in neutrophil membranes and reduce cyclic 
AMP a~umulation in intact neutrophils [5]. These 
reports suggest that human neutrophils contain 
functional cr*-adrenoceptors. Therefore, activation 
of a*-adrenoceptors on human neutrophils would be 
expected to attenuate the effects of /I-adrenoceptor 
agonists, which inhibit fMLP-stimulated 0; pro- 
duction, presumably through activation of adenylyl 
cyclase (see Ref 1). However, in the present study, 
the selective, potent and structurally unrelated rx2- 
adrenoceptor agonists BHT 920 and UK 14304 failed 
to attenuate the inhibitory effects of isoprenaline 
(see Fig. 1). Furthermore, both BHT 920 and UK 
14304 had no effect on fMLP-stimulated 0; 
production alone. The partial agonists clonidine and 
oxymetazoline (~~-adren~ptor selective) also had 
no effect on either UP-stimulated 02 production 
or the inhibition by isoprenaline of fMLP-stimulated 
0, production. Thus, over a range of structural 
classes and potencies of as-adrenoceptor agonists, 
no effects on 0; production were seen. A possible 
interpretation of the results of the present study is 
that as-adrenoceptors are ~mp~ental~ed in 
intact cells, so that they cannot interact with Gi to 
inhibit adenylyl cyclase activated bytgadrenoceptors. 
Therefore, we sought a more direct functional 
correlate of #z-adrenoceptor activation. 
In many cell types q-adrenoceptors modulate 
[Ca”]i. In some cell types, such 8s HEL cells and 
smooth muscle cells, cu2-adrenoceptor activation 
results in an increase in [Ca’+]i [6,21,22]. In platelets 
cuz-adrenoceptor activation results in potentiation of 
[Ca”]i increases produced by other stimuli [23]. We 
studied neutrophils and a widely used model of 
neutrophils, differentiated HL-60 cells. Dif- 
ferentiated HL-60 cells express many of the receptors 
found in neutrophils, including padrenoceptors [24], 
express similar G-proteins (Gis, Gh and G, [25]), 
and the receptors are functionally coupled to G- 
proteins and effecters [l]. Thus, if neutrophils 
express ~~-adrenocepto~, it might be reasonably 
assumed that I-IL-60 cells would also express ai- 
adrenoceptors. We also studied HEL cells, a cell 
line known to possess a2-adrenoceptors 1211, 
activation of which increases [Ca2’]i [6] as a positive 
control. As found for 0, production, a range of oz- 
adrenoceptor agonists, belonging to st~~turally 
unrelated classes, was ineffective in either producing 
an increase in [Ca*+]i or potentiating the effect of 
UTP in human neutrophiis or differentiated HL-60 
cells (Fig. 2 and unpublished data). However, UK 
14304, adrenaline and BHT 920 produced clear 
effects in HEL cells with UK 14034 and adrenaline 
giving increases in ]Ca2’]i similar to those reported 
by Michel et al. [4] (Fig. 2 and unpublished data). 
We then sought further evidence that cx2- 
adrenoceptors functionally coupled to G-proteins 
are present in neutrophils of HL-60 cells. Activation 
of receptors linked to G-proteins resultsin stimulation 
of the high-affinity GTPase associated with the (Y- 
subunits (see Refs 2627). Thus, if rut-adrenoceptors 
were being activated, we should observe an 
increase in high-affinity GTPase activity. For these 
experiments and the binding experiments (see below) 
we used only membranes from the HL-60 myeloid 
cell line and HEL cells as there is no practical way 
to exclude completely the presence of platelets in 
neutrophil preparations. Platelets have a high 
number of o*ut-adrenoceptors [16], and the presence 
of even a small proportion of their membranes could 
produce a false positive result. 
UK 14304 produced a significant increase in 
GTPase activity in membranes from HEL cells (see 
Table 1). However, UK 14304 did not produce a 
si~ificant increase in hip-affinity GTPase activity 
in membranes from differentiated HL-60 cells (see 
Table I). Receptor-mediated activation of high- 
affinity GTPase could be demonstrated in membranes 
from the differentiated HL-60 cells, as shown by the 
response to fMLP (see Table 1). Thus, we have no 
evidence for functional coupling of cr2-adrenoceptors 
to G-proteins in HL-60 cells. 
The above results raised the question of whether 
HL-60 cells actually have cyz-adrenoceptor binding 
sites. Therefore, we studied the binding of [3H]- 
RX821002, an cuz-adrenoceptor antagonist reported 
to have superior properties for detecting cw2- 
adrenoceptors [16,17], to membranes from HEL 
and HL-60 cells, Membranes from HEL cells 
demonstrated specific, saturable, high-affinity bind- 
ing of [3H]RX821002, consistent with the increases 
in GTPase activity and increases in [Ca*+]i (see Fig. 
3). The B,, and KD values for binding of [3H]- 
RX821002 to HEL membranes in the present study 
are consistent with previously published data [6,16]. 
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In contrast, neither membranes from the HL-60 
promyelocytes nor from the differentiated HL-60 
cells demonstrated saturable high-affinity binding 
(see Fig. 3). 
Taken together the results of the present study 
suggest hat HL-60 promyelocytes and differentiated 
HL-60 cells do not possess mz-adrenoceptors. This 
also suggests that the lack of effect of az-adrenoceptor 
agonists on 0; production in neutrophils in the 
present study is therefore due to a lack of mz- 
adrenoceptors. While it might appear unusual for 
Padrenoceptor stimulation to be unopposed by Q- 
adrenoceptors, there are other examples of cells 
which show fiadrenoceptor-mediated stimulation of 
adenylyl cyclase without concomitant cu,-adreno- 
ceptor-mediated inhibition (e.g. cardiac myocytes, 
see reviews in Refs 22,28). 
The question arises as to the reason for the 
discrepancy between the results in the present study 
on intact neutrophils and the results of Panosian and 
Marinetti [4] and Verghese et al. [5] in neutrophil 
membranes. Differences between the binding 
characteristics of [3H]RX821002 and [3H]yohimbine 
are unlikely to explain this, if anything [3H]RX821002 
should be a more sensitive ligand that [3H]yohimbine 
[16-191. A possibility is that in both membrane and 
whole cell preparations the presence of platelet 
membranes and platelets, respectively, could be 
responsible. Panosian and Marinetti [4] reported 
that their neutrophil preparations had typically less 
than two platelets per neutrophil. As platelets can 
have a B,,, of 168 fmol/mg protein as determined 
by [3H]yohimbine binding [16], this number of cells 
would be a significant source of binding sites in any 
membrane preparation. The B,,, of 5 fmol/mg 
protein that Panosian and Marinetti [4] found with 
t3H]yohimbine in neutrophil membranes could well 
be due to uncorrected platelet contamination. 
A similar argument applies to the modulation of 
cyclic AMP levels reported in preparations of intact 
neutrophils [4] and adenylyl cyclase activity in 
membranes [5], as platelets have an adenylyl cyclase 
which is lO-20-fold more active than that of 
neutrophils [29], and which shows substantial 
inhibition by the platelet az-adrenoceptors [29]. 
Thus, a significant proportion of the observed 
adenylyl cyclase activity (and its modulation) could 
be due to platelets. Furthermore, Bokoch [29] using 
highly purified neutrophil membranes, found a2- 
adrenoceptor agonists did not inhibit adenylyl 
cyclase. In contrast to measurements of adenylyl 
cyclase activity or CAMP content, measurement of 
0; production is free from interference from 
residual platelets, as platelets do not produce 0, in 
response to fMLP. 
In conclusion, using various experimental 
approaches to rule out the possible effect of platelet 
contamination, we could not find any evidence that 
neutrophils have functional az-adrenoceptors. In the 
light of our findings the reported presence and effects 
of these receptors are most likely due to the almost 
unavoidable contamination by platelets in neutrophil 
preparations. 
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